(NASDAQ: OBIO) Orchestra Biomed Holdings's forecast annual revenue growth rate of -24.27% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.99%.
Orchestra Biomed Holdings's revenue in 2026 is $32,724,000.On average, 9 Wall Street analysts forecast OBIO's revenue for 2026 to be $28,254,835, with the lowest OBIO revenue forecast at $23,473,240, and the highest OBIO revenue forecast at $35,838,608. On average, 9 Wall Street analysts forecast OBIO's revenue for 2027 to be $41,574,162, with the lowest OBIO revenue forecast at $23,473,240, and the highest OBIO revenue forecast at $85,509,661.
In 2028, OBIO is forecast to generate $1,055,876,648 in revenue, with the lowest revenue forecast at $322,757,054 and the highest revenue forecast at $2,323,251,981.